Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932274 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53ALDH1A1POLBBRD4 | |
| SCHEMBL25609365 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2TP53ALDH1A1POLBBRD4 | |
| SCHEMBL21042902 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL8259396 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1POLBHTTKDM4E | |
| SCHEMBL15998913 | 0.81 | ATM (0.47) | SMN1; SMN2TP53ALDH1A1POLBBRD4 | |
| SCHEMBL21042943 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL12102748 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL4971987 | 0.80 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1GAAATM | |
| SCHEMBL2606791 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL11923163 | 0.80 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-03-03 | — | — | US | disclosed |
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161468-A1 | BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | CYP3A7, CYP2A7, CYP2J2 | SMN1; SMN2 2717/4885TP53 4374/4885ALDH1A1 424/4885 |
| US-10577346-B2 | Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof | CYP3A7, UGT2B7, BDKRB1 | SMN1; SMN2 2759/4885TP53 4161/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.